REPLIGEN CORP — Director's Dealing 2018

Sep 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2018-09-10

Reporting Person: Hunt Anthony (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-10	Common Stock	M	11873	$16.55	Acquired	255017	Direct
2018-09-10	Common Stock	S	27566	$57.7091	Disposed	227451	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-10	Stock Option (Right to Buy)	$16.55	M	11873	Disposed	2024-05-05	Common Stock (11873)	Direct

Footnotes

F1: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 17, 2017.

F2: $57.7091 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.18 to $58.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: 10,000 shares vest and become exercisable on each of the following dates: 5/05/2015, 5/05/2016, 5/05/2017, 5/05/2018 and 5/05/2019.